In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme

Not yet recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 30, 2025

Conditions
HealthyHypercholesterolemiaHypertensionOverweightPrediabetesDiabetesFamily History of Coronary Artery DiseaseFamily History of Peripheral Artery DiseaseFamily History of Cerebrovascular Disease
Interventions
DRUG

PCSK9 Antibody, PCSK9 Enzyme

In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

LifeBridge Health

OTHER

NCT06675994 - In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme | Biotech Hunter | Biotech Hunter